Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Bevacizumab Antibody Affinity Maturation to Improve Ovarian Cancer Immunotherapy: In Silico Approach Publisher



Eyvazi S1 ; Payandeh Z2 ; Khalili S3 ; Sefid F4 ; Ouladsahebmadarek E5
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  2. 2. Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
  3. 3. Department of Biology Sciences, Shahid Rajaee Teacher Training University, Tehran, Iran
  4. 4. Departeman of Medical Genetics, Shahid Sadoughi University of Medical Science, Yazd, Iran
  5. 5. Women’s Reproductive Health Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

Source: International Journal of Peptide Research and Therapeutics Published:2019


Abstract

Ovarian cancer is one of the most lethal gynecologic cancers. The high mortality rate is due to lack of early symptoms and developing drug resistance. Immunotherapy has emerged as a promising approach to treatment of cancer. Bevacizumab is a recombinant humanized monoclonal IgG antibody against VEGF A that used in cancer immunotherapy, especially in ovarian cancer therapy. For a successful cancer immunotherapy the different features of therapeutic antibodies such as binding affinity should be improved. Increased affinity enhances the biological action of the antibody, which in turn improves the therapeutic effects. Furthermore, the increased antibody affinity can reduce the therapeutic dose of the antibody, resulting in lower toxicity and handling cost. Considering the importance of this issue, using in silico analysis, we aimed to find the important amino acids of the Bevacizumab antibody, and then replaced these amino acids with others to improve antibody binding affinity. Finally, we examined the binding affinity of antibody variants to antigens. In conclusion, the designed antibodies could be potential candidates for binding to antigens with improved affinity. © 2018, Springer Nature B.V.
Related Docs
View other Related Docs
1. Ofatumumab Monoclonal Antibody Affinity Maturation Through in Silico Modeling, Iranian Biomedical Journal (2018)
2. Overview of Cd24 As a New Molecular Marker in Ovarian Cancer, Journal of Cellular Physiology (2019)
3. A Novel Molecular Design for a Hybrid Phage-Dna Construct Against Dkk1, Molecular Biotechnology (2018)
4. Structure Based Screening for Inhibitory Therapeutics of Ctla-4 Unveiled New Insights About Biology of Acth, International Journal of Peptide Research and Therapeutics (2020)
5. Affinity Maturation and Characterization of the Ofatumumab Monoclonal Antibody, Journal of Cellular Biochemistry (2019)
6. In Silico Analysis for Determination and Validation of Human Cd20 Antigen 3D Structure, International Journal of Peptide Research and Therapeutics (2019)
7. Immune Therapy of Melanoma: Overview of Therapeutic Vaccines, Journal of Cellular Physiology (2019)
8. Design of an Engineered Ace2 As a Novel Therapeutics Against Covid-19, Journal of Theoretical Biology (2020)
Experts (# of related papers)
View all Related Experts
Mohammad Reza Khorramizadeh (1)
Mahdi Mohebali (1)
Other Related Docs
9. In Silico Characterization of Epitopes for Vaccine Design Against Escherichia Coli Based on Heme-Utilization Protein, Journal of Applied Biotechnology Reports (2024)
10. In Silico Approaches for the Design and Optimization of Interfering Peptides Against Protein–Protein Interactions, Frontiers in Molecular Biosciences (2021)
11. In Silico Analysis for Determination and Validation of Iron-Regulated Protein From Escherichia Coli, International Journal of Peptide Research and Therapeutics (2019)
12. Anti-Tumour Activity of Tivozanib, a Pan-Inhibitor of Vegf Receptors, in Therapy-Resistant Ovarian Carcinoma Cells, Scientific Reports (2017)
13. Construction of a Recombinant Phage-Vaccine Capable of Reducing the Growth Rate of an Established Ll2 Tumor Model, Iranian Journal of Allergy# Asthma and Immunology (2018)
14. Structural Analyses of the Interactions Between the Thyme Active Ingredients and Human Serum Albumin; [Kekik Aktif Maddeler Ile Insan Serum Albuminleri Arasindaki Etkilesimlerin Yapisal Analizleri], Turkish Journal of Biochemistry (2017)
15. Computational Design and Analysis of a Poly-Epitope Fusion Protein: A New Vaccine Candidate for Hepatitis and Poliovirus, International Journal of Peptide Research and Therapeutics (2020)
16. Bioinformatics Prediction and Experimental Validation of Vh Antibody Fragment Interacting With Neisseria Meningitidis Factor H Binding Protein, Iranian Journal of Basic Medical Sciences (2020)
17. Antibody-Drug Therapeutic Conjugates: Potential of Antibody-Sirnas in Cancer Therapy, Journal of Cellular Physiology (2019)
18. An Update on Antiviral Antibody-Based Biopharmaceuticals, International Immunopharmacology (2020)
19. Pierce Into Structural Changes of Interactions Between Mutated Spike Glycoproteins and Ace2 to Evaluate Its Potential Biological and Therapeutic Consequences, International Journal of Peptide Research and Therapeutics (2022)
20. Design and Construction of a Fusion Peptide Containing B1, B2, B4, and Epc1 Epitopes for Diagnosis of Human Cystic Echinococcosis, Iranian Journal of Public Health (2019)
21. Impact of Snps, Off-Targets, and Passive Permeability on Efficacy of Bcl6 Degrading Drugs Assigned by Virtual Screening and 3D-Qsar Approach, Scientific Reports (2022)
22. Sars-Cov-2 Proteome Harbors Peptides Which Are Able to Trigger Autoimmunity Responses: Implications for Infection, Vaccination, and Population Coverage, Frontiers in Immunology (2021)
23. Liothyronine Could Block the Programmed Death-Ligand 1 (Pdl1) Activity: An E-Pharmacophore Modeling and Virtual Screening Study, Journal of Receptors and Signal Transduction (2022)